EMH.V - Emerald Health Therapeutics, Inc.

TSXV - TSXV Delayed Price. Currency in CAD
4.50
-0.31 (-6.44%)
As of 12:23PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.81
Open4.48
Bid4.50 x 0
Ask4.51 x 0
Day's Range4.28 - 4.64
52 Week Range1.37 - 9.68
Volume829,509
Avg. Volume1,319,920
Market Cap615.825M
Beta (3Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.15
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.75
  • ACCESSWIRE5 hours ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • GlobeNewswireyesterday

    Emerald Health Therapeutics Files 17 Patent Applications Covering Defined Dose™ Cannabis Products

    OTCQX:EMHTF) has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose™ cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use.  The products provide more precise and consistent delivery, dosage, and formulations.

  • GlobeNewswire6 days ago

    Emerald Health Therapeutics Promotes Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing

    OTCQX:EMHTF) (“Emerald”) today announced the promotion of Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing. “Paul has been instrumental in preparing the Emerald brand for adult-use legalization in Canada,” said Chris Wagner, Chief Executive Officer of Emerald.

  • GlobeNewswire7 days ago

    MediPharm Labs Corp. and Emerald Health Therapeutics, Inc. Sign Cannabis Concentrate Program Agreement

    MediPharm Labs Corp. ("MediPharm") (LABS.V) is pleased to announce that it has entered into a Cannabis Concentrate Program Agreement (the "Agreement") with Emerald Health Therapeutics Inc. ("Emerald") (TSXV: EMH - OTCQX:EMHTF). Pursuant to the Agreement, signed on October 5, 2018, Emerald will provide MediPharm with dried cannabis to create premium quality cannabis oil (the "Program"). The Agreement enables Emerald to provide pharmaceutical grade cannabis concentrate products produced by MediPharm to its large base of registered patients, as well as provide adult-use recreational consumers with premium quality cannabis concentrates commencing October 17, 2018.

  • GlobeNewswire7 days ago

    Emerald Health Therapeutics’ Subsidiary Northern Vine Receives International Government Approvals and Completes Import and Export of Cannabis Oils for Research & Development

    OTCQX:EMHTF) (“Emerald”) announced today that Northern Vine Canada Inc. (Northern Vine), a wholly owned subsidiary of Emerald, successfully completed the export of cannabis oil to the United States on May 25 pursuant to an import permit from the federal U.S. Drug Enforcement Agency (DEA). The cannabidiol (CBD)-containing cannabis oil is expected to be used by a US biopharmaceutical company to develop its proprietary cannabinoid technology for medical research and development and for its manufacturing process for future clinical trials.

  • GlobeNewswire8 days ago

    Emerald Health Therapeutics’ Wholly Owned Subsidiary Northern Vine to Participate in Series of Cannabis Testing Seminars Hosted by Thermo Fisher Scientific

    VICTORIA, British Columbia, Oct. 09, 2018 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Northern Vine Canada Inc..

  • GlobeNewswire14 days ago

    Emerald Health Therapeutics Enters Research Agreement with VivaCell Biotechnologies to Evaluate Proprietary Cannabis Products

    OTCQX:EMHTF) (“Emerald”) has entered into a research agreement with VivaCell Biotechnologies Spain S.L.U. (“VivaCell”). VivaCell is an institute focused on cannabis research, which will provide its cannabis-industry-leading contract research organization (CRO) services to Emerald to elucidate the mechanism of action of proprietary formulations and dosage forms that Emerald is developing. This collaboration has the potential to strengthen Emerald’s intellectual property portfolio and assist in establishing Emerald as a leader in the development of proprietary cannabis products for medical-use and improved adult-use products with more precise and consistent delivery, dosage, and formulations.

  • GlobeNewswire21 days ago

    Emerald Health Therapeutics Secures Long-term Supply of Hemp for CBD Extraction

    OTCQX:EMHTF) (“Emerald”) has agreed to purchase from Emerald Health Hemp Inc. (EHH) CBD-containing hemp biomass for extraction into CBD oil. EHH has established agreements to purchase approximately 500 acres of harvested hemp chaff, plant material consisting mainly of flower and leaf,  in Manitoba and Prince Edward Island in 2018, with a plan to expand field operations in 2019. Emerald has signed an agreement with EHH to purchase approximately 500 acres of chaff in 2018 and approximately 1,000 acres in 2019 to 2022, with an option to renew for an additional two-year period.

  • ACCESSWIRE29 days ago

    Today's Research Reports on Hemostemix, TSO3, Emerald Health Therapeutics and DiaMedica Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • GlobeNewswirelast month

    Emerald Health Therapeutics Named as Cannabis Supplier by Newfoundland Labrador Liquor Corporation to Provide Adult-Use Cannabis Products

    OTCQX:EMHTF) (“Emerald”) has been selected as an authorized cannabis supplier by the Newfoundland Labrador Liquor Corporation ("NLC") to supply cannabis products to the NLC and serve the adult-use market throughout the province of Newfoundland Labrador starting October 17. “We’re proud to work with the NLC as a preferred Licensed Producer to serve Newfoundland and Labrador in the upcoming legal cannabis market,” said Chris Wagner, CEO at Emerald. With its previously announced supply agreements with the provinces of British Columbia and Ontario, as well as its commercial production facilities quickly ramping up in British Columbia and Quebec, Emerald is prepared for the adult-use market.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Confirms Supply Agreement with Ontario Cannabis Retail Corporation to Supply Adult-Use Cannabis Products

    OTCQX:EMHTF) (“Emerald”) today announced that it has been selected as an approved supplier by the Ontario Cannabis Retail Corporation, operating as the Cannabis Retail Store (“OCS”), to supply the province of Ontario with its cannabis products in anticipation of the adult-use market starting October 17, 2018. Quantities will be disclosed once details have been released by the Province of Ontario. “We’re proud to partner with the OCS to provide adults in Ontario with the opportunity to discover our products,” said Chris Wagner, CEO at Emerald.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Announces Amendment from Health Canada for Pure Sunfarms’ Cultivation License, Expanding Cannabis Production Area to Approximately 550,000 Square Feet in One of the Single Largest Cannabis Growing Facilities in the World

    OTCQX:EMHTF) (“Emerald”) and Village Farms International, Inc. (“Village Farms” or the “Company”) (VFF.TO) (VFFIF) today announced that their 50/50 joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its fourth amendment to the cultivation license for its Delta 3 greenhouse in Delta, BC. This amendment permits Pure Sunfarms to expand its cannabis production area to 550,000 square feet – half of the 1.1 million square foot Delta 3 production facility. The newly licensed area is expected to be in full production by mid-October of this year.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Reports 2nd Quarter 2018 Financial Results and Provides Corporate Update

    OTCQX:EMHTF) (“Emerald” or “the Company”) has filed its financial statements and management discussion and analysis for the three and six months ended June 30, 2018. “Since the start of the second quarter, we acquired and began cultivating cannabis at our Quebec-based licensed producer Agro-Biotech, substantially increased our licensed cannabis production area at our Pure Sunfarms joint venture to roughly 420,000 square feet, and obtained from Health Canada Pure Sunfarms’ sales license.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

    OTCQX:EMHTF) (“Emerald”) today announced that Chris Wagner, Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 20th Annual Global Investment Conference taking place at the St. Regis Hotel in New York, NY. An archived version of the webcast will be available for 90 days in the investor section of the Emerald Health Therapeutics website.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Signs Term Sheet to Access Large-Scale Extraction, Softgel Production, and New Product Development Capabilities Through Strategic Alliance with Factors Group of Nutritional Companies

    OTCQX:EMHTF) (“Emerald”) today announced that it has signed a term sheet to form a strategic alliance with Factors R&D Technology, Inc. (“FTI”), a division of Factors Group of Nutritional Companies Inc. In this exclusive arrangement, FTI will provide to Emerald pharmaceutical-grade, industrial-scale manufacturing capacity as well as expertise in GMP-level extraction, softgel production, and packaging focused on the rapidly emerging market opportunities for medicinal cannabis in Canada and internationally. This collaboration leverages the Factors Group’s decades of experience in product development, formulation and innovation.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Engages Acorn Management Partners for Investor Relations

    VICTORIA, British Columbia, Aug. 24, 2018-- Emerald Health Therapeutics, Inc. today announced that it has engaged Acorn Management Partners, an Atlanta-based investor relations firm, to provide investor ...

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Announces Amendment to Pure Sunfarms’ Cultivation License, Substantially Expanding Cannabis Production Area to Approximately 420,000 Square Feet

    OTCQX:EMHTF) (“Emerald”) and Village Farms International, Inc. (VFF.TO) (VFFIF) today announced that their 50/50 joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its third amendment to the cultivation license for its Delta 3 greenhouse in Delta, BC. This amendment permits Pure Sunfarms to expand its cannabis production area by 195,000 square feet to approximately 420,000 square feet of the 1.1-million square foot Delta 3 production facility. The newly licensed area will be in commercial production this week, as the Delta 3 nursery has been producing cuttings in anticipation of this expansion.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Announces Appointment of Pure Sunfarms President and CEO

    OTCQX:EMHTF) (“Emerald”) and Village Farms International, Inc. (VFF.TO) (VFFIF) today announced that Mandesh Dosanjh has been appointed President and Chief Executive Officer of Pure Sunfarms Corp., their 50/50 owned cannabis joint venture, effective on or before October 1, 2018. Mr. Dosanjh joins Pure Sunfarms from his position as Senior Vice President, Supply Chain and Wholesale, at the Liquor Control Board of Ontario (LCBO), where he led LCBO’s supply chain division, and developed and managed its supply chain and wholesale strategy as the LCBO prepared for the legalization of adult-use cannabis.

  • ACCESSWIRE2 months ago

    Today's Research Reports on CRH Medical, TSO3, Emerald Health Therapeutics, and DiaMedica Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 20, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Completes Acquisition of Licensed Dealer Northern Vine Canada

    Northern Vine is a Licensed Dealer (LD) under the provisions of the Canadian Controlled Drugs and Substances Act. The dealer license allows Emerald to participate in the growing market for cannabis analytical testing, which Emerald expects to grow in conjunction with increasing cannabis production volumes in Canada.

  • GlobeNewswire2 months ago

    Abattis Completes Sale of Northern Vine Interest

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce that it has completed the sale (the “Sale”) of its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) to Emerald Health Therapeutics, Inc. (TSXV:EMH / OTCQX:EMHTF) (“Emerald”) in exchange for $2 million in cash and $4 million in common shares of Emerald, 50% of which are free trading and 50% of which may be sold in 30 days. The share purchase agreement governing the Disposition (the “Agreement”) also provides that, upon Northern Vine and/or Emerald earning gross revenues of $10 million from the sale of products or provision of services to customers introduced by Abattis, Emerald will issue Abattis an additional $4 million in common shares of Emerald.

  • GlobeNewswire2 months ago

    Emerald Health Expands into Analytical Testing and Import/Export -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Emerald Health Therapeutics Inc.'s (EMH.V) (EMHTF) recent acquisition of a dealer license from Abattis Bioceuticals Corp. that enables it to compete in emerging market verticals. For example, Canopy Growth Corp.’s Tweed Inc. acquired a dealer license back in December 2016.

  • CNW Group3 months ago

    Village Farms International's Cannabis Joint Venture Pure Sunfarms Receives Sales License from Health Canada for 1.1 Million Square Foot Greenhouse

    OTCQX: EMHTF) ("Emerald") today announced that their 50/50 joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received its cannabis sales license from Health Canada. Pure Sunfarms is now permitted to immediately begin selling product from its expanding inventory of high-quality dried cannabis, including to Emerald Health Therapeutics, under their previously announced supply agreement, as well as to address significant demand from other licensed producers. This sales license also positions Pure Sunfarms to secure supply agreements with provincial government distributors for the imminent legal adult-use marketplace.

  • GlobeNewswire3 months ago

    Emerald Health Therapeutics’ Cannabis Joint Venture Pure Sunfarms Receives Sales License from Health Canada for 1.1 Million Square Foot Greenhouse

    Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF) (“Emerald”) and Village Farms International, Inc. (“Village Farms”) (VFF.TO) (VFFIF) today announced that their 50/50 joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received its cannabis sales license from Health Canada. Pure Sunfarms is now permitted to immediately begin selling product from its expanding inventory of high-quality dried cannabis, including to Emerald Health Therapeutics, under their previously announced supply agreement, as well as to address significant demand from other licensed producers. This sales license also positions Pure Sunfarms to secure supply agreements with provincial government distributors for the imminent legal adult-use marketplace.

  • GlobeNewswire3 months ago

    Emerald Health Therapeutics Signs Cannabis Supply Memorandum of Understanding with British Columbia Liquor Distribution Branch

    Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF) (“Emerald”) has signed a Memorandum of Understanding ("MOU") with the British Columbia Liquor Distribution Branch ("BCLDB") to supply its high-quality cannabis products to the BCLDB to serve the adult-use market throughout the province. “Emerald has a strong relationship with the BCLDB team, and our new supply partnership will allow us to provide them with local access to our large cannabis production capacity,” said Chris Wagner, CEO at Emerald.